Kyverna Reports Positive Phase 2 Data in Myasthenia Gravis

Kyverna Therapeutics, Inc. ( (KYTX) ) has provided an update.

On April 20, 2026, Kyverna Therapeutics reported positive longer-term Phase 2 data from its KYSA-6 registrational trial of miv-cel in patients with generalized myasthenia gravis, showing deep, durable clinical responses through one year after a single dose. The company highlighted that all seven treated patients achieved rapid, sustained improvements in key disease scores, high rates of minimal symptom expression, and discontinuation of chronic immunosuppressive therapies, while maintaining a favorable safety profile with no high-grade cytokine release syndrome or neurotoxicity, reinforcing confidence in the ongoing Phase 3 portion of KYSA-6 and Kyverna’s positioning in CAR T-based neuroimmunology.

Biomarker data indicated robust CAR T-cell expansion, deep B-cell depletion, and signs of immune reset with reduced autoantibody levels and preserved humoral immunity, supporting miv-cel’s differentiated profile. KYSA-6 was amended into an FDA-aligned Phase 2/3 registrational design in 2025, and Kyverna is currently enrolling the Phase 3 trial across 14 active sites in three geographies, underscoring the potential of miv-cel to redefine treatment for generalized myasthenia gravis with a single-dose, durable, drug-free remission approach.

The most recent analyst rating on (KYTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.

Spark’s Take on KYTX Stock

According to Spark, TipRanks’ AI Analyst, KYTX is a Neutral.

The score is held down primarily by very weak financial performance—no recent revenue, widening losses, and accelerating cash burn—despite a relatively strong low-debt balance sheet. Technical indicators add near-term caution (negative MACD, RSI below 50, price below key short-term averages). Positive corporate events (board and CTO upgrades) provide some support but do not offset the current loss and burn profile.

To see Spark’s full report on KYTX stock, click here.

More about Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with a particular emphasis on neuroimmunology. Its lead product candidate is miv-cel (mivocabtagene autoleucel, KYV-101), an autologous CD19-targeting CAR T-cell therapy designed to induce deep B-cell depletion and an immune reset, initially targeting generalized myasthenia gravis and stiff person syndrome, with additional studies in multiple sclerosis and rheumatoid arthritis.

Average Trading Volume: 703,708

Technical Sentiment Signal: Strong Buy

Current Market Cap: $568.1M

For an in-depth examination of KYTX stock, go to TipRanks’ Overview page.